ストックスクリーナーアプリを入手
51.33
0.52%
-0.27
プレマーケット:
51.28
-0.05
-0.10%
前日終値:
$51.60
開ける：
$52.165
24時間の取引高:
1.18M
Relative Volume:
0.69
時価総額：
$5.51B
収益：
$761.41M
当期純損益:
$98.16M
株価収益率:
62.74
EPS:
0.8181
ネットキャッシュフロー:
$141.79M
1週間 パフォーマンス:
+10.10%
1か月 パフォーマンス:
+20.80%
6か月 パフォーマンス:
-33.03%
1年 パフォーマンス:
-30.58%
1日の値動き範囲:
$51.00
$52.16
1週間の範囲:
$45.73
$52.50
52週間の値動き範囲:
$28.66
$91.00
Corcept Therapeutics Inc Stock (CORT) Company Profile
名前
Corcept Therapeutics Inc
セクター
電話
650.688.8803
住所
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
51.33 | 5.54B | 761.41M | 98.16M | 141.79M | 0.8181 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-26 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2025-12-31 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2025-12-16 | 開始されました | UBS | Neutral |
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2023-11-06 | アップグレード | Truist | Hold → Buy |
| 2023-04-11 | 開始されました | SVB Securities | Market Perform |
| 2023-04-04 | 開始されました | Piper Sandler | Overweight |
| 2023-02-15 | ダウングレード | Jefferies | Buy → Hold |
| 2022-08-01 | ダウングレード | Truist | Buy → Hold |
| 2022-07-27 | アップグレード | Jefferies | Hold → Buy |
| 2022-06-27 | 再開されました | Canaccord Genuity | Buy |
| 2022-02-02 | 開始されました | Canaccord Genuity | Buy |
| 2022-01-28 | 開始されました | Truist | Buy |
| 2020-08-05 | ダウングレード | Jefferies | Buy → Hold |
| 2019-09-24 | 開始されました | Jefferies | Buy |
| 2019-09-06 | 開始されました | H.C. Wainwright | Buy |
| 2019-02-04 | ダウングレード | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 繰り返されました | Stifel | Hold |
| 2018-05-31 | ダウングレード | Stifel | Buy → Hold |
| 2018-03-09 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 開始されました | Stifel | Buy |
| 2017-02-02 | 開始されました | Ladenburg Thalmann | Buy |
| 2015-04-21 | 開始されました | FBR Capital | Outperform |
| 2014-01-13 | ダウングレード | Stifel | Buy → Hold |
| 2013-08-09 | ダウングレード | Janney | Buy → Neutral |
| 2013-08-09 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2010-01-06 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 開始されました | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | アップグレード | Punk, Ziegel & Co | Mkt Perform → Accumulate |
すべてを表示
Corcept Therapeutics Inc (CORT) 最新ニュース
Corcept (NASDAQ: CORT) CEO sells 40K shares under 10b5-1 plan - Stock Titan
Corcept Therapeutics (NASDAQ: CORT) affiliate plans sale of 20,000 shares via Stifel - Stock Titan
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2026 Earnings Call Transcript - Insider Monkey
Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co. - Moomoo
H.C. Wainwright Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $75 - Moomoo
Corcept (CORT) Q1 2026 Earnings Transcript - The Globe and Mail
Corcept (CORT) Q4 2025 Earnings Transcript - The Globe and Mail
Corcept (CORT) Q1 2025 Earnings Transcript - The Globe and Mail
CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures - TradingView
CORT Maintained by HC Wainwright & Co. -- Price Target Raised to $75 - GuruFocus
CORT DEADLINE: ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class ActionCORT - TMX Newsfile
MSN Money - MSN
symbol__ Stock Quote Price and Forecast - CNN
Corcept (CORT) Upgraded After Key Regulatory Approval for Lifyorli - Yahoo Finance
Corcept Therapeutics Shakes Up Nasdaq Index Fund Radar - Kalkine Media
CORT Maintained by Piper Sandler -- Price Target Raised to $88 - GuruFocus
Corcept Therapeutics Guides Higher on Lifyorli-Fueled Revenue Growth - The Globe and Mail
Corcept Therapeutics Is Maintained at Overweight by Piper Sandler - Moomoo
Corcept Therapeutics (NASDAQ:CORT) Stock Price Up 7.9%Time to Buy? - MarketBeat
Corcept Therapeutics (CORT) insider notifies sale of 40,000 shares via Stifel - Stock Titan
CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised - The Globe and Mail
Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk - Benzinga
Corcept Therapeutics Incorporated Q1 2026 Earnings Call Summary - Yahoo Finance
Corcept Therapeutics Inc (CORT) Q1 2026 Earnings Call Highlights - GuruFocus
CORT Stock Price, Quote & Chart | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
Corcept Therapeutics (NASDAQ:CORT) Announces Earnings Results - MarketBeat
Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Corcept Therapeutics (CORT) Reports Promising Two-Year Survival Data - GuruFocus
Corcept Therapeutics (NASDAQ:CORT) Revenue Miss Leads to Q1 Net Loss, But Guidance Upgrade and Lifyorli Launch Signal Strong Momentum - ChartMill
Corcept Therapeutics Q1 Earnings Call Highlights - MarketBeat
CORT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Is Corcept Therapeutics (CORT) 8.8% Undervalued After Q1 2026 Mi - GuruFocus
Corcept Therapeutics Q1 2026 Earnings Call Transcript - Benzinga
Earnings call transcript: Corcept Therapeutics Q1 2026 raises guidance amid Lifyorli launch - Investing.com Canada
Corcept (NASDAQ:CORT) Misses Q1 CY2026 Revenue Estimates - TradingView
Corcept: Q1 Earnings Snapshot - WKYC
Corcept Therapeutics Q1 Swings to Loss, Revenue Rises; Raises Full-Year Guidance - marketscreener.com
Earnings Flash (CORT) Corcept Therapeutics Posts Q1 Per Share Loss $-0.30 - marketscreener.com
(CORT) Corcept Therapeutics Expects 2026 Revenue Range $950M-$1.05B, vs. FactSet Est of $899.5M - marketscreener.com
Earnings Flash (CORT) Corcept Therapeutics Incorporated Reports Q1 Revenue $164.9M, vs. FactSet Est of $185.8M - marketscreener.com
Corcept reports survival data from ALS drug trial By Investing.com - Investing.com Canada
Higher costs and Lifyorli launch reshape Corcept (NASDAQ: CORT) in Q1 - Stock Titan
FDA cancer approval lifts Corcept (NASDAQ: CORT) 2026 outlook and spend - Stock Titan
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis - Business Wire
Corcept earnings on deck: Can new cancer drug offset losses? By Investing.com - Investing.com Canada
Corcept Therapeutics Inc (CORT) - MSN
Corcept Earnings: What To Look For From CORT - Yahoo Finance
Corcept Therapeutics (CORT) Inspires Confidence with ROSELLA Phase 3 Survival Data - Insider Monkey
Corcept Therapeutics IncorporatedCommon Stock (NQ: CORT - FinancialContent
Corcept falls as appeals court sides with Teva in Korlym patent dispute - MSN
Corcept Therapeutics (CORT) Projected to Post Earnings on Thursday - MarketBeat
Corcept Therapeutics Inc (CORT) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):